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Background: COVID-19 is associated with a substantial risk of venous thrombotic 
events, even in the presence of adequate thromboprophylactic therapy.
Objectives: We aimed to better characterize the hypercoagulable state of COVID-19 
patients in patients receiving anticoagulant therapy.
Methods: We took plasma samples of 23 patients with COVID-19 who were on pro-
phylactic or intensified anticoagulant therapy. Twenty healthy volunteers were in-
cluded to establish reference ranges.
Results: COVID-19 patients had a mildly prolonged prothrombin time, high von 
Willebrand factor levels and low ADAMTS13 activity. Most rotational thromboelas-
tometry parameters were normal, with a hypercoagulable maximum clot firmness in 
part of the patients. Despite detectable anti-activated factor X activity in the major-
ity of patients, ex vivo thrombin generation was normal, and in vivo thrombin genera-
tion elevated as evidenced by elevated levels of thrombin-antithrombin complexes 
and D-dimers. Plasma levels of activated factor VII were lower in patients, and levels 
of the platelet activation marker soluble CD40 ligand were similar in patients and 
controls. Plasmin-antiplasmin complex levels were also increased in patients despite 
an in vitro hypofibrinolytic profile.
Conclusions: COVID-19 patients are characterized by normal in vitro thrombin gen-
eration and enhanced clot formation and decreased fibrinolytic potential despite the 
presence of heparin in the sample. Anticoagulated COVID-19 patients have persis-
tent in vivo activation of coagulation and fibrinolysis, but no evidence of excessive 
platelet activation. Ongoing activation of coagulation despite normal to intensified 
anticoagulant therapy indicates studies on alternative antithrombotic strategies are 
urgently required.
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1  | INTRODUC TION
Patients with COVID-19 have a profound risk for venous thrombotic 
events. Particularly in patients admitted to an intensive care unit 
(ICU), rates of deep vein thrombosis and pulmonary embolism are 
exceedingly high, even in the presence of pharmacological throm-
boprophylaxis.1,2 In addition to macrovascular thrombotic events, 
microvascular thrombosis has been proposed to contribute to dis-
ease progression, with pulmonary clots contributing to respiratory 
failure,3-5 and clots in other vascular beds to multiple organ failure.6,7 
Anticoagulant treatment has been shown to reduce mortality, per-
haps because of reduction of microvascular thromboses.8
The high thrombosis risk in COVID-19 patients has been linked to 
a hypercoagulable state that has not been well defined. The in vivo 
hyperactivation of coagulation appears to be linked to a massive in-
flammatory response coupled with increases in acute phase proteins 
including fibrinogen,9 and involvement of neutrophil extracellular traps 
(NETs),10 which are newly recognized actors in thrombosis. Routine he-
mostasis tests show mild prolongations in prothrombin time and acti-
vated partial thromboplastin time, and mild thrombocytopenia in some 
patients, but massively elevated levels of D-dimer in many patients,9 
that appear to have prognostic value.11 Whole blood thromboelas-
tography has demonstrated a hypercoagulable profile,12,13 and one of 
these studies concluded that the COVID-19 coagulopathy does not 
have elements of typical disseminated intravascular coagulation, as has 
been suggested by others.13 Notably, increased (major) bleeding com-
plications have been described in COVID-19 patients, especially in the 
critically ill, suggesting a fragile balance in hemostatic status of these 
patients,14 although others have demonstrated bleeding risks compa-
rable to patients with non-COVID-19 acute respiratory syndromes.
In a large academic medical center in Barcelona, Spain, to which 
approximately 600 patients were admitted at the peak of the 
COVID-19 pandemic, the initial reports on thrombosis and hyperco-
agulability and their own observations led to an intensified throm-
boprophylactic regimen for part of the admitted COVID-19 patients, 
particularly those with more advanced disease. Although an anti-
coagulant protocol was instituted, during the period of our study, 
this protocol was poorly adhered to and individualized decisions on 
anticoagulant dosing were taken. We aimed to study the effects of 
this individualized anticoagulant therapy on the hemostatic status of 
these patients.
2  | MATERIAL S AND METHODS
2.1 | Patients
We included 23 patients that were admitted with COVID-19 (which 
was confirmed by PCR) to Hospital Clínic Barcelona, Spain, in April 
2020. Almost all patients received the low molecular weight hepa-
rin (LMWH) enoxaparin. Ethical approval from the Medical Ethical 
Committee Hospital Clínic Barcelona (2020/0371) was obtained. All 
patients, or in the case of incapacity their consultee, gave informed 
consent or assent, respectively, for participation in this study. 
Twenty healthy controls were included to establish reference val-
ues for the various assays performed. Exclusion criteria for healthy 
controls were age younger 18 years, pregnancy, hereditary throm-
bophilia or hemophilia, use of anticoagulant medications, history of 
venous thromboembolic events, and blood (product) transfusion up 
to 7 days before inclusion.
2.2 | Sampling
Citrated blood samples were taken 4 (2-6) days after admission to the 
hospital (9 [6-13] days after onset of symptoms) on either a general 
ward or ICU by venipuncture or from dedicated arterial lines. In all 
patients, anticoagulation was started on admission. Blood samples 
were either used immediately for rotational thromboelastometry 
(ROTEM) measurements or processed to platelet-poor plasma within 
30 minutes of the blood draw by double centrifugation at 2500g for 
15 minutes, and subsequently stored at −80°C until used for analy-
ses. Complete blood cell counts, and creatinine, total bilirubin, and 
C-reactive protein were measured as part of routine clinical care by 
the Centre de Diagnòstic Biomèdic at the Hospital Clínic Barcelona.
2.3 | Assays
We measured PT, activated partial thromboplastin time, international 
normalized ratio, prothrombin, antithrombin, fibrinogen, and D-dimer 
on an automated coagulation analyzer (STACompact 3, Stago) using 
reagents and protocols from the manufacturer. Von Willebrand factor 
(VWF) plasma levels were determined with an in-house ELISA using com-
mercially available polyclonal antibodies against VWF (DAKO). Plasma 
K E Y W O R D S
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Essentials
• COVID-19 patients are at increased risk for venous 
thrombotic events, despite thromboprophylaxis.
• Hemostatic status of 23 COVID-19 patients on antico-
agulant therapy was studied in plasma.
• In vitro: normal coagulation, enhanced clot formation 
and hypofibrinolysis despite heparin.
• Persistent in vivo activation of coagulation and fibrinoly-
sis despite anticoagulant therapy.
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activity of a disintegrin and metalloproteinase with a thrombospondin 
type 1 motif, member 13 (ADAMTS13) was measured using the FRETS-
VWF73 assay (Peptanova). Levels of VWF and ADAMTS13 in pooled 
normal plasma were set at 100%, and values obtained in test plasmas 
were expressed as a percentage of pooled normal plasma. Plasminogen 
activator inhibitor type 1 levels were quantified by commercially avail-
able ELISA from R&D Systems. Cell-free DNA was quantified using the 
Quant-iT PicoGreen dsDNA assay kit (Fisher Scientific), as described 
previously.16 The concentration of myeloperoxidase DNA complexes in 
plasma was determined by ELISA, as previously described.17
ROTEM analyses were performed on a ROTEM sigma accord-
ing to the manufacturers’ instructions. Thrombin generation was 
performed as previously described18 using commercially available 
reagents containing recombinant tissue factor (final concentration: 
5 pmol/L), phospholipids (final concentration: 4 µmol/L), and soluble 
thrombomodulin (the concentration of which is not revealed by the 
manufacturer) (Thrombinoscope BV). Anti-activated factor X (anti-Xa) 
levels were measured on an automated analyzer (ACL 300 TOP) using 
Heparin LRT (Hyphen Biomed).
Plasma fibrinolytic potential was estimated by studying lysis of 
a tissue factor-induced clot by exogenous tissue plasminogen acti-
vator by monitoring changes in turbidity during clot formation and 
subsequent lysis, as described previously.19 Samples that were still 
clotted at 3 hours after the start of the experiment were arbitrarily 
assigned a clot lysis time (CLT) of 180 minutes.
Plasma levels of thrombin-antithrombin (TAT) complexes, pro-
thrombin fragment 1 + 2 (F1 + 2), plasmin-antiplasmin (PAP) com-
plexes, and soluble CD40 ligand were quantified by commercially 
available ELISAs (Siemens, for TAT and F1 + 2, Technoclone, for PAP, 
and R&D Systems, Bio-techne, for sCD40L). Plasma levels of acti-
vated factor VII were quantified using the Hemoclot factor VIIa kit 
(Hyphen Biomed).
2.4 | Statistical analyses
Statistical analyses were performed using GraphPad Prism, version 
8.3.1 (San Diego, CA). The results were presented as numbers (per-
centages) for categorical variables and medians [interquartile ranges] 
for continuous variables. Test results were compared between 
COVID-19 patients and healthy controls, and between patients ad-
mitted to the ICU and the ward, using the Mann-Whitney U test. 
Relations between laboratory parameters were made by simple linear 
regression. P values < .05 were considered statistically significant.
3  | RESULTS AND DISCUSSION
3.1 | Abnormalities in diagnostic hemostasis tests in 
COVID-19 patients
We studied 23 patients of whom 12 were admitted to the ICU, with 
11 on general wards. None of the ward patients later had to be 
admitted to the ICU. Three ICU patients developed thrombotic com-
plications: one pulmonary embolism, one myocardial infarction, and 
one distal ischemia of the fingers. General patient characteristics are 
shown in Table 1. Most ICU patients received higher anticoagulant 
doses compared with ward patients; Table 1). Routine diagnostic he-
mostasis tests and plasma levels of markers for NETs are shown in 
Table 2. Compared with healthy controls, patients had a prolonged 
prothrombin time and international normalized ratio, which are 
largely explained by decreased FVII levels that strongly correlated 
with the prothrombin time (r2 = .56, P < .0001). In addition, patients 
had a decreased platelet count, elevated fibrinogen levels, slightly 
decreased levels of prothrombin and antithrombin, high levels of 
VWF and FVIII, and low levels of ADAMTS13. Of note, four patients 
had prothrombin and antithrombin levels < 25%, and two other pa-
tients had ADAMTS13 levels < 10%. These results are consistent 
with a mild consumption coagulopathy with a thrombogenic VWF 
profile. Plasma levels of plasminogen activator inhibitor type 1 were 
approximately 3.7 times higher in COVID-19 patients compared 
with controls. Markers of NETs were modestly elevated in patients 
compared with controls, and did not differ between patients that 
were or were not admitted to ICU, which may argue against a key 
role of NETs in the pathogenesis of COVID-19 associated sequelae, 
as was suggested previously. Indeed, unlike previously described,10 
NET markers in our cohort did not correlate with C-reactive protein, 
D-dimer, platelet count, or use of mechanical ventilation.
3.2 | Normal to hypercoagulable ex vivo 
clot formation, thrombin generation, and mild 
hypofibrinolysis
We next studied hemostatic potential of COVID-19 patients by 
three global tests (Table 3). ROTEM parameters were largely 
within the normal range, except for elevated maximum clot firm-
ness in extem, intem, and fibtem in 6, 8, and 11 patients, respec-
tively. A limitation of these analyses was that normal ranges were 
not locally established, but taken from the ROTEM user manual. 
Of note, ROTEM extem and fibtem reagents contain polybrene, 
which neutralizes heparin present in many of these samples. 
Thrombomodulin-modified thrombin generation was preserved 
on a group level, but individual patients were clearly hyper- or hy-
pocoagulable. The patient samples that generated little thrombin 
contained high levels of LMWH as evidenced by anti-Xa activity 
assays, whereas hypercoagulable samples generally had low to 
undetectable anti-Xa activity, although one patient had marked 
thrombin generation even in the presence of high anti-Xa levels. 
ETP and peak thrombin levels were inversely correlated with anti-
Xa levels (r2 = .16, P = .055 and r2 = .20, P = .03; without one 
clear outlier, these correlations became much stronger r2 = .54, 
P < .0001 and r2 = .50, P = .0002). Samples taken from patients 
admitted to the ICU generated substantially less thrombin, but 
this was directly related to much higher anti-Xa levels in samples 
taken from patients on the ICU compared with ward patients 
4  |     BLASI et AL.


















Age 64 [53-74] 69 [57-76] 58 [42-74] 44 [39-50] <.001 .267
Female 9 (39%) 6 (50%) 3 (27%) 9 (45%) .697 .265
Body mass index 
(kg/m2)
30 [27-34] 32 [27-35] 29 [27-31] 24 [20-27] <.0001 .285
SOFA score 3.0 [1.0-6.0] 5.5 [3.3-7.8] 2.0 [0.0-3.0] .01




Intubated 12 (52%) 12 (100%) 0 (0%) <.0001
Noninvasive 
ventilation
1 (4%) 0 (0%) 1 (9%) .286
Nasal oxygen 10 (43%) 0 (0%) 10 (91%) <.0001
PaO2/FiO2 (PaFI) 367 [208-420] 239 [130-414] 418 [325-420] .121
Respiratory rate (/
min)
22 [18-28] 27 [26-32] 18 [18-20] .0002
SIRS criteria (≥2) 8 (35%) 6 (50%) 2 (18%) .110
DIC score (≥5) 2 (9%) 1 (8%) 1 (9%) .949
Glasgow coma scale 
(≤8)




13 (57%) 8 (67%) 5 (45%) .305
Cirrhosis 5 (22%) 1 (8%) 4 (36%) .104
Diabetes 4 (17%) 2 (17%) 2 (18%) .924
Onset of symptoms 
before admission 
(days)
6 [5-8] 7 [5-10] 6 [5-7] .626
Blood sampling day 
(since admission)
4 [2-6] 5 [4-7] 2 [1-2] <.0001
Baseline laboratory values





2.33 [0.70-5.57] 0.77 
[0.42-2.59]
3.28 [2.33-8.96] .009
Lactate (mg/dL) 15 [12-16] 15 [13-19] 15 [9-15] .374
LDH (U/L) 307 [236-424] 345 [258-660] 305 [193-354] .300










6.3 [3.4-11.8] 10.5 [6.7-15.3] 3.5 [3.1-4.5] 5.88 [5.26-7.93] .995 .007
Anticoagulation (LMWH)
No 2 (9%) 0 (0%) 2 (18%) .122
<0.5 mg/kg/d 7 (30%) 2 (17%) 5 (45%)a  .134
0.5-1.5 mg/kg/d 9 (39%) 6 (50%) 3 (27%) .265
≥1.5 mg/kg/d 5 (22%) 4 (33%)b  1 (9%) .159
(Continues)
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(Table 3). Because samples were not taken at specific time points 
relative to the last LMWH injection, and because there was a 
substantial difference in dosing and timing of LMWH administra-
tion between ICU and ward, this likely explains the difference in 
anti-Xa and thrombin generating capacity between ICU and ward 
patients.
Plasma CLT was higher in COVID-19 patients compared to 
healthy controls, but similar between patients on ICU and ward. 
Five patients had substantially elevated CLT (>100 minutes). Two 
of these had underlying liver disease and may have been hypo-
fibrinolytic related to decompensating liver disease as we have 




















hospital stay in 
days (n = 21)
25 [7.5-44] 43 [21-46] 11 [5.0-26] .015
Still in hospital 2 (9%) 2 (17%) 0 (0%) .157
Death 4 (17%) 2 (17%) 2 (18%) .924
Note: The results are presented as median [interquartile range] for continuous variables, and number (percentage) for categorical variables. 
Comparisons between the two groups are made using the Mann-Whitney U test or chi-squared test, as appropriate.
Abbreviations: DIC, disseminated intravascular coagulation; ICU, intensive care unit; LDH, lactate dehydrogenase; LMWH, low-molecular-weight 
heparin; SIRS, systemic inflammatory response syndrome; SOFA, sequential organ failure assessment; WBC, white blood cell.
aOne patient received tinzaparin sodium 3500 International Units per day. 
bOne ICU patient received intravenous infusion of unfractionated heparin. 
TA B L E  1   (Continued)
TA B L E  2   Various laboratory values in healthy controls and COVID patients with additional subdivision in ICU and non-ICU patients
Controls (n = 20)
COVID-19 Patients 




PT (s) 10.9 [10.7-11.3] 15.9 [15.3-18.6] <.0001 15.6 [15.2-16.4] 18.6 [15.8-19.8] .046
APTT (s) 33.4 [31.4-35.0] 34.6 [31.2-39.7] .113 33.7 [31.2-41.5] 36.0 [31.2-39.7] .707
INR 1.01 [0.99-1.05] 1.15 [1.11-1.34] <.0001 1.13 [1.10-1.19] 1.34 [1.15-1.42] .049
Platelet count (109/L) 244 [184-323] 167 [136-250] .039 196 [127-293] 167 [154-239] .940
Additional hemostasis tests
Fibrinogen (g/L) 3.00 [2.77-3.50] 4.51 [2.82-5.15] .021 3.93 [3.00-4.88] 5.02 [1.72-5.52] .413
Prothrombin (%) 130 [113-144] 85 [50-99] <.0001 84 [64-96] 87 [48-100] .893
Antithrombin (%) 113 [104-126] 102 [51-121] .016 106 [76-126] 85 [43-115] .206
VWF (%) 132 [95.5-176] 306 [200-421] <.0001 367 [296-464] 216 [180-319] .015
FVIII (%)a  88 [72-110] 161 [129-216] <.0001 172 [136-235] 160 [96-195] .234
FVII (%)a  90 [81-99] 71 [55-85] .0034 76 [66-91] 60 [44-78] .052
ADAMTS13 (%) 101 [83.3-116] 47.3 [25.8-66.1] <.0001 46.2 [27.4-57.8] 59.9 [25.8-70.3] .449
PAI-1 (ng/mL) 0.70 [0.33-1.45] 2.60 [2.00-3.08] <.0001 2.35 [1.70-3.08] 2.60 [2.00-5.30] .705
NET markers
Cell-free DNA (µg/mL) 0.89 [0.87-0.96] 1.28 [1.15-1.45] <.0001 1.33 [1.27-1.47] 1.22 [1.12-1.37] .062
MPO-DNA complexes 
(AU)
0.07 [0.05-0.10] 0.14 [0.10-0.57] <.001 0.13 [0.09-0.17] 0.18 [0.12-0.79] .094
Note: The results are presented as median [interquartile range]. Comparisons between the two groups were made using the Mann-Whitney U test for 
nonparametric data.
Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; APTT, activated partial 
thromboplastin time; ICU, intensive care unit; INR, international normalized ratio; MPO, myeloperoxidase; NET, neutrophil extracellular trap; PAI-1, 
plasminogen activator inhibitor type 1; PT, prothrombin time; VWF, von Willebrand factor.
aMissing data of one (non-ICU) patient for FVII and FVIII analyses (n = 22). 
6  |     BLASI et AL.
ICU, and hypofibrinolysis is a common feature of patients that 
are critically ill. Viscoelastic tests have shown evidence of fibri-
nolytic shutdown in one-quarter of COVID-19 patients and fibri-
nolytic shutdown was associated with thrombosis.21 However, 
the definition of hypofibrinolysis using viscoelastic tests is not 
straightforward because “no lysis” is in fact part of the reference 
range.22 We found “no lysis” (defined as CLT > 180 minutes) in 
only three patients (13%), whereas our plasma-based test detects 
“no lysis” in a much larger proportion of other patient popula-
tions (notably postsurgery23 and patients with acute liver failure 
[73.5%]24). This suggests that a true fibrinolytic shutdown is rare 
in COVID-19, which is also evidenced by highly elevated D-dimer 
and plasmin-antiplasmin complexes (see the following section). 
Importantly, LMWH decreases CLT across physiologically rele-
vant concentrations,25 which may be why plasma clot lysis was 
only mildly impaired in our patients.
Thus, COVID-19 patients have somewhat elevated clot forma-
tion, likely related to hyperfibrinogenemia, normal thrombin gener-
ating capacity despite the presence of LMWH, and hypofibrinolysis 
despite the presence of LMWH.
TA B L E  3   Global hemostatic tests










CT Ex (s) 50-80 70.0 [65.5-72.8] 70.5 [66.3-75.0] 69.5 [64.0-71.0] .352
MCF Ex (mm) 55-72 68.0 [64.5-74.3] 71.0 [67.0-75.8] 66.5 [61.8-69.5] .154
LY60 Ex (%) 94-100 99.5 [96.0-100] 100 [100-99.3] 96.0 [94.5-97.8] <.001
CT Int (s) 161-204 180 [164-204] 193 [179-228] 170 [157-178] .013
MCF Int (mm) 51-69 64.5 [60.8-71.3] 68.0 [63.3-71.8] 62.0 [57.0-68.5] .261
MCF Fibtem (mm) 6-21 21.5 [13.8-26.0] 20.5 [13.3-23.0] 24.5 [17.5-29.0] .144
TGA
ETP (nmol/L IIa × min) 385 [243-515] 472 [153-807] .328 185 [7.75-459] 789 [663-841] .002
Peak (nmol/L IIa) 77.5 [47.3-126] 100 [25.0-176] .348 40.0 [1.89-95.8] 168 [145-186] .008
Lag time (min) 2.17 [1.67-2.33] 2.33 [1.67-3.00] .236 2.33 [1.59-3.15] 2.33 [1.67-3.00] .682
Velocity index (nmol/L 
IIa/ min)
31.0 [15.8-62.8] 54.0 [19.0-82.0] .265 26.0 [1.50-62.8] 74.0 [54.0-88.0] .022
Anti-Xa (U/mL) 0.13 [0.03-0.61] 0.44 [0.18-0.65] 0.03 [0.00-0.12] .008
CLT (min) 68.1 [59.8-71.7] 80.8 [69.5-94.3] .007 83.8 [70.6-99.4] 74.7 [61.2-89.9] .449
Note: The results are presented as median [interquartile range]. Comparisons between the two groups were made using the Mann-Whitney U test for 
nonparametric data.
Abbreviations: anti-Xa, anti-activated factor X; CLT, clot lysis time; CT, clot time; ETP, endogenous thrombin potential; Ex, extrinsic TEM; ICU, 
intensive care unit; In, intrinsic TEM; LY60% of maximum MCF at 60 minutes; MCF, maximal clot firmness; ROTEM, rotational thromboelastometry; 
TGA, thrombin generation assay.
aMissing data of one (non-ICU) patient for ROTEM analyses (n = 22). 
TA B L E  4   Markers of in vivo activation of coagulation, fibrinolysis, and platelets
Controls (n = 20)
COVID-19 Patients 
(n = 23) P Value ICU (n = 12) Non-ICU (n = 11)
P 
Value
D-dimera  (ng/mL) 208 [157-309] 1110 [573-5305] <.0001 2535 [860-7848] 565 [425-2188] .025
TAT (µg/mL) 1.55 [1.40-2.20] 7.30 [4.50-12.2] <.0001 7.15 [4.45-8.78] 11.8 [4.50-24.1] .355
F1 + 2 (pmol/L) 206 [158-269] 191 [145-314] .966 218 [140-449] 186 [145-314] .964
VIIaa  (mU/mL) 52.0 [41.8-63.6] 27.2 [21.7-41.7] .002 32.2 [24.5-45.2] 25.5 [10.2-30.1] .069
PAP (ng/mL) 193 [170-240] 984 [648-2377] <.0001 862 [484-2324] 1017 [730-2590] .309
sCD40L (ng/mL) 52.0 [16.5-129] 83.0 [33.0-177] .465 52.0 [20.0-148] 130 [63.0-183] .217
Note: The results are presented as median [interquartile range]. Comparisons between the two groups were made using the Mann-Whitney U test for 
nonparametric data.
Abbreviations: F1 + 2, prothrombin fragment F1 + 2; ICU, intensive care unit; PAP, plasmin-antiplasmin; sCD40L, soluble CD40 Ligand; TAT, 
thrombin-antithrombin; VII(a), (activated) blood coagulation factor VII.
aMissing data of one (non-ICU) patient for D-dimer and VIIa. 
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3.3 | Ongoing in vivo activation of coagulation and 
fibrinolysis despite low therapeutic anticoagulation in 
COVID-19 patients
In vivo markers of activation of coagulation are shown in Table 4. 
TAT and PAP complex levels are strongly elevated in patients 
with COVID-19, indicating ongoing thrombin and plasmin genera-
tion in COVID-19 patients despite anticoagulation with LMWH. 
Interestingly, TAT and PAP levels were not different between pa-
tients admitted to the ICU or to the general ward, whereas D-dimer 
levels were substantially higher in ICU compared with ward pa-
tients. This may indicate that ICU patients have a higher clot burden, 
which may be primarily intrapulmonary clots,26,27 despite similar 
procoagulant activity. This might be explained by decreased (local) 
anticoagulant capacity in ICU patients, perhaps related to increased 
endothelial injury that decreases availability of thrombomodulin 
and endogenous heparinoids. Surprisingly, F1 + 2 levels were not in-
creased in COVID-19 patients compared with controls, and we have 
no explanation for the discrepancy between TAT and F1 + 2 levels. 
D-dimer and TAT levels were not correlated to anti-Xa levels, but 
F1 + 2 levels were inversely correlated with anti-Xa levels (r2 = .22, 
P = .03). The VIIa levels were lower in patients, which may point to 
consumption of VIIa similar to what we have previously observed in 
patients during the acute phase of deep vein thrombosis.28 Indeed, 
VIIa levels strongly positively correlated with zymogen VII levels 
(r2 = .59, P = <.0001). Soluble CD40 ligand levels were similar be-
tween patients and controls, suggesting COVID-19 patients are not 
characterized by excessive platelet activation.
Taken together, our data confirm a hypercoagulable status of 
enhanced thrombin generating capacity, enhanced ex vivo clot for-
mation likely related to hyperfibrinogenemia, and a decreased ex 
vivo fibrinolytic capacity in patients with COVID-19. Interestingly, 
despite normal to intensified anticoagulant treatment, in vivo ac-
tivation of coagulation and fibrinolysis was evident and indepen-
dent of anti-Xa levels, whereas in vitro activation of coagulation 
proportionally decreased as a function of anti-Xa levels. Our ob-
servations that the hypercoagulable profile is more pronounced in 
the sicker patients are in line with the hypothesis that activation of 
coagulation, particularly in the pulmonary circulation, is a key fea-
ture of COVID-19 and may contribute to progression of disease.26 
These data suggest that low therapeutic anticoagulant regimens 
are often insufficient to downregulate coagulation activation in 
COVID-19 patients, and call for assessment of alternative or inten-
sified antithrombotic strategies. However, careful individual pa-
tient assessment (especially in the critically ill) is warranted, given 
the increased bleeding risk that is associated with COVID-19.
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